89 related articles for article (PubMed ID: 23007551)
1. Antitumor action of α(1)-adrenoceptor blockers on human bladder, prostate and renal cancer cells.
Gotoh A; Nagaya H; Kanno T; Nishizaki T
Pharmacology; 2012; 90(5-6):242-6. PubMed ID: 23007551
[TBL] [Abstract][Full Text] [Related]
2. Naftopidil induces apoptosis in malignant mesothelioma cell lines independently of α1-adrenoceptor blocking.
Masachika E; Kanno T; Nakano T; Gotoh A; Nishizaki T
Anticancer Res; 2013 Mar; 33(3):887-94. PubMed ID: 23482758
[TBL] [Abstract][Full Text] [Related]
3. Naftopidil, a selective {alpha}1-adrenoceptor antagonist, suppresses human prostate tumor growth by altering interactions between tumor cells and stroma.
Hori Y; Ishii K; Kanda H; Iwamoto Y; Nishikawa K; Soga N; Kise H; Arima K; Sugimura Y
Cancer Prev Res (Phila); 2011 Jan; 4(1):87-96. PubMed ID: 21205739
[TBL] [Abstract][Full Text] [Related]
4. Novel naftopidil-related derivatives and their biological effects as alpha1-adrenoceptors antagonists and antiproliferative agents.
Huang J; He F; Huang M; Liu X; Xiong Y; Huang Y; Zhu L; Yang Y; Xu X; Yuan M
Eur J Med Chem; 2015; 96():83-91. PubMed ID: 25874333
[TBL] [Abstract][Full Text] [Related]
5. Piperazine-based Alpha-1 AR Blocker, Naftopidil, Selectively Suppresses Malignant Human Bladder Cells via Induction of Apoptosis.
Nakagawa YU; Nagaya H; Miyata T; Wada Y; Oyama T; Gotoh A
Anticancer Res; 2016 Apr; 36(4):1563-70. PubMed ID: 27069132
[TBL] [Abstract][Full Text] [Related]
6. Reduction of prostate cancer incidence by naftopidil, an α1 -adrenoceptor antagonist and transforming growth factor-β signaling inhibitor.
Yamada D; Nishimatsu H; Kumano S; Hirano Y; Suzuki M; Fujimura T; Fukuhara H; Enomoto Y; Kume H; Homma Y
Int J Urol; 2013 Dec; 20(12):1220-7. PubMed ID: 23600973
[TBL] [Abstract][Full Text] [Related]
7. Novel HER2 selective tyrosine kinase inhibitor, TAK-165, inhibits bladder, kidney and androgen-independent prostate cancer in vitro and in vivo.
Nagasawa J; Mizokami A; Koshida K; Yoshida S; Naito K; Namiki M
Int J Urol; 2006 May; 13(5):587-92. PubMed ID: 16771730
[TBL] [Abstract][Full Text] [Related]
8. Relative cytotoxic potencies and cell death mechanisms of α1 -adrenoceptor antagonists in prostate cancer cell lines.
Forbes A; Anoopkumar-Dukie S; Chess-Williams R; McDermott C
Prostate; 2016 Jun; 76(8):757-66. PubMed ID: 26880388
[TBL] [Abstract][Full Text] [Related]
9. Naftopidil, a selective alpha-1 adrenoceptor antagonist, inhibits growth of human prostate cancer cells by G1 cell cycle arrest.
Kanda H; Ishii K; Ogura Y; Imamura T; Kanai M; Arima K; Sugimura Y
Int J Cancer; 2008 Jan; 122(2):444-51. PubMed ID: 17918159
[TBL] [Abstract][Full Text] [Related]
10. Differential effects of prazosin and naftopidil on pelvic blood flow and nitric oxide synthase levels in spontaneously hypertensive rats.
Yono M; Yamamoto Y; Imanishi A; Yoshida M; Ueda S; Latifpour J
J Recept Signal Transduct Res; 2008; 28(4):403-12. PubMed ID: 18702011
[TBL] [Abstract][Full Text] [Related]
11. 1-[2-(2-Methoxyphenylamino)ethylamino]-3-(naphthalene-1-yloxy)propan-2-ol as a potential anticancer drug.
Kanno T; Tanaka A; Shimizu T; Nakano T; Nishizaki T
Pharmacology; 2013; 91(5-6):339-45. PubMed ID: 23817168
[TBL] [Abstract][Full Text] [Related]
12. Suppression of human prostate cancer cell growth by alpha1-adrenoceptor antagonists doxazosin and terazosin via induction of apoptosis.
Kyprianou N; Benning CM
Cancer Res; 2000 Aug; 60(16):4550-5. PubMed ID: 10969806
[TBL] [Abstract][Full Text] [Related]
13. [Pharmacological properties of naftopidil, a drug for treatment of the bladder outlet obstruction for patients with benign prostatic hyperplasia].
Ikegaki I
Nihon Yakurigaku Zasshi; 2000 Aug; 116(2):63-9. PubMed ID: 10976457
[TBL] [Abstract][Full Text] [Related]
14. [The growth inhibition effect of alpha-adrenoceptor antagonists on androgen- independent prostate cancer cell line].
Liu SJ; Xu KX; Wang XF; Hou SK; Wang YC
Zhonghua Wai Ke Za Zhi; 2004 May; 42(10):604-6. PubMed ID: 15265404
[TBL] [Abstract][Full Text] [Related]
15. Prostate growth inhibition by subtype-selective alpha(1)-adrenoceptor antagonist naftopidil in benign prostatic hyperplasia.
Kojima Y; Sasaki S; Oda N; Koshimizu TA; Hayashi Y; Kiniwa M; Tsujimoto G; Kohri K
Prostate; 2009 Oct; 69(14):1521-8. PubMed ID: 19544328
[TBL] [Abstract][Full Text] [Related]
16. Anti-angiogenic effects and mechanism of prazosin.
Liao CH; Guh JH; Chueh SC; Yu HJ
Prostate; 2011 Jun; 71(9):976-84. PubMed ID: 21541974
[TBL] [Abstract][Full Text] [Related]
17. Anoikis induction by quinazoline based alpha 1-adrenoceptor antagonists in prostate cancer cells: antagonistic effect of bcl-2.
Keledjian K; Kyprianou N
J Urol; 2003 Mar; 169(3):1150-6. PubMed ID: 12576871
[TBL] [Abstract][Full Text] [Related]
18. Growth inhibiting effects of terazosin on androgen-independent prostate cancer cell lines.
Xu K; Wang X; Ling M; Wong Y
Chin Med J (Engl); 2003 Nov; 116(11):1673-7. PubMed ID: 14642133
[TBL] [Abstract][Full Text] [Related]
19. Alpha1-adrenoceptor antagonists radiosensitize prostate cancer cells via apoptosis induction.
Cuellar DC; Rhee J; Kyprianou N
Anticancer Res; 2002; 22(3):1673-9. PubMed ID: 12168853
[TBL] [Abstract][Full Text] [Related]
20. Comparison of two alpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study.
Nishino Y; Masue T; Miwa K; Takahashi Y; Ishihara S; Deguchi T
BJU Int; 2006 Apr; 97(4):747-51, discussion 751. PubMed ID: 16536766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
